These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 15989913

  • 1. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
    O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ.
    Am J Med; 2005 Jul; 118(7):778-81. PubMed ID: 15989913
    [No Abstract] [Full Text] [Related]

  • 2. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
    Howden CW.
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
    [Abstract] [Full Text] [Related]

  • 3. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
    Miner PB, Allgood LD, Grender JM.
    Aliment Pharmacol Ther; 2007 Jan 01; 25(1):103-9. PubMed ID: 17229225
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Place and significance of proton pump inhibitors in current treatment of peptic ulcers].
    Maev IV.
    Eksp Klin Gastroenterol; 2003 Jan 01; (3):12-13. PubMed ID: 14989296
    [No Abstract] [Full Text] [Related]

  • 6. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
    Horn JR, Howden CW.
    Aliment Pharmacol Ther; 2005 Dec 01; 22 Suppl 3():20-4. PubMed ID: 16303033
    [Abstract] [Full Text] [Related]

  • 7. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
    Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, Kilander A.
    Aliment Pharmacol Ther; 2006 Sep 15; 24(6):945-54. PubMed ID: 16948806
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
    Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E, Bednarczyk E, Morse GD.
    Pharmacotherapy; 2006 Mar 15; 26(3):341-6. PubMed ID: 16503713
    [Abstract] [Full Text] [Related]

  • 10. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT, Chapman W, Neumann CS, Gearty JC.
    Aliment Pharmacol Ther; 2006 Mar 15; 23(6):727-33. PubMed ID: 16556174
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of two antacid preparations on intragastric acidity--a two-centre open randomised cross-over placebo-controlled trial.
    Sulz MC, Manz M, Grob P, Meier R, Drewe J, Beglinger C.
    Digestion; 2007 Mar 15; 75(2-3):69-73. PubMed ID: 17496418
    [Abstract] [Full Text] [Related]

  • 13. Review article: the clinical pharmacology of proton pump inhibitors.
    Sachs G, Shin JM, Howden CW.
    Aliment Pharmacol Ther; 2006 Jun 15; 23 Suppl 2():2-8. PubMed ID: 16700898
    [Abstract] [Full Text] [Related]

  • 14. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors.
    Pfefferkorn MD, Croffie JM, Gupta SK, Molleston JP, Eckert GJ, Corkins MR, Fitzgerald JF.
    J Pediatr Gastroenterol Nutr; 2006 Feb 15; 42(2):160-5. PubMed ID: 16456408
    [Abstract] [Full Text] [Related]

  • 15. Solubility and bioavailability of stabilized amorphous calcium carbonate.
    Meiron OE, Bar-David E, Aflalo ED, Shechter A, Stepensky D, Berman A, Sagi A.
    J Bone Miner Res; 2011 Feb 15; 26(2):364-72. PubMed ID: 20690187
    [Abstract] [Full Text] [Related]

  • 16. Proton pump inhibitors for GERD in children.
    Med Lett Drugs Ther; 2007 Feb 26; 49(1255):17-8. PubMed ID: 17325623
    [No Abstract] [Full Text] [Related]

  • 17. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.
    Kukanich B, Lascelles BD, Aman AM, Mealey KL, Papich MG.
    J Vet Pharmacol Ther; 2005 Oct 26; 28(5):461-6. PubMed ID: 16207309
    [Abstract] [Full Text] [Related]

  • 18. Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors.
    Frazzoni M, Manno M, De Micheli E, Savarino V.
    Dig Liver Dis; 2007 May 26; 39(5):415-21. PubMed ID: 17379591
    [Abstract] [Full Text] [Related]

  • 19. Proton pump inhibitors reduce the bioavailability of dietary vitamin C.
    Henry EB, Carswell A, Wirz A, Fyffe V, McColl KE.
    Aliment Pharmacol Ther; 2005 Sep 15; 22(6):539-45. PubMed ID: 16167970
    [Abstract] [Full Text] [Related]

  • 20. Noncardiac chest pain and proton pump inhibitors.
    Bobba RK, Arsura EL.
    Arch Intern Med; 2006 Jan 23; 166(2):248; author reply 248-9. PubMed ID: 16432099
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.